Cargando…
Risk of hypertension in cancer patients treated with abiraterone: a meta-analysis
BACKGROUND: Hypertension is one of the major side effects associated with abiraterone in the treatment of advanced prostate cancer. The specific contribution of abiraterone to hypertension has not been defined. We performed a systematic review and meta-analysis of randomized clinical trials to deter...
Autores principales: | Zhu, Xiaolei, Wu, Shenhong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6545007/ https://www.ncbi.nlm.nih.gov/pubmed/31168403 http://dx.doi.org/10.1186/s40885-019-0116-x |
Ejemplares similares
-
Risk of hypertension in Cancer patients treated with Abiraterone: a meta-analysis
por: Zhu, Xiaolei, et al.
Publicado: (2019) -
Risks and management of hypertension in cancer patients undergoing targeted therapy: a review
por: Zhu, Xiaolei, et al.
Publicado: (2022) -
Prognostic factors for patients treated with abiraterone
por: Alvim, Cecília M, et al.
Publicado: (2019) -
The Utility of 24-h Ambulatory Blood Pressure Monitoring for the Diagnosis and Management of White Coat Hypertension in a Primary Care Setting
por: Zhu, Xiaolei, et al.
Publicado: (2022) -
Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide
por: Rana, Dikshyanta, et al.
Publicado: (2021)